Emergence of a R-type CA2+ channel (CAV 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
View Patent ↗The invention relates to methods and products for treatment of a neurological defect such as a subarachnoid hemorrhage or cerebral vasospasm. Specifically, R-type voltage-gated calcium channel inhibitors and related compositions and kits are described.
1. A method for treating cerebral vasospasm, comprising:
administering to a subject in need thereof an effective amount for treating cerebral vasospasm of an R-type voltage-dependent calcium channel inhibitor,
wherein the R-type voltage-dependent calcium channel inhibitor is an expression inhibitor, and
wherein the expression inhibitor is an antisense oligonucleotide or siRNA molecule.
2. The method of claim 1 , wherein the R-type voltage-dependent calcium channel inhibitor is administered within 96 hours after subarachnoid hemorrhage has occurred.
3. The method of claim 1 , wherein the R-type voltage-dependent calcium channel inhibitor is administered within 1 week after subarachnoid hemorrhage has occurred.
4. The method of claim 1 , wherein the R-type voltage-dependent calcium channel inhibitor is administered during surgery to treat subarachnoid hemorrhage.
5. The method of claim 1 , wherein the R-type voltage-dependent calcium channel inhibitor is administered intravenously.
6. The method of claim 1 , wherein the R-type voltage-dependent calcium channel inhibitor is administered during surgery.
7. The method of claim 1 , wherein the subject does not have symptoms of cerebral vasospasm.
8. The method of claim 1 , wherein the subject has symptoms of cerebral vasospasm.
9. A method for treating cerebral vasospasm, comprising:
administering to a subject in need thereof an effective amount for treating cerebral vasospasm of an R-type voltage-dependent calcium channel inhibitor,
wherein the R-type voltage-dependent calcium channel inhibitor is an expression inhibitor,
wherein the R-type voltage dependent calcium channel inhibitor is administered by infusion into cerebrospinal fluid, and
wherein the R-type voltage dependent calcium channel inhibitor is an antisense oligonucleotide.
10. The method of claim 9 , wherein the R-type voltage-dependent calcium channel inhibitor is administered within 96 hours after subarachnoid hemorrhage has occurred.
11. The method of claim 9 , wherein the R-type voltage-dependent calcium channel inhibitor is administered within 1 week after subarachnoid hemorrhage has occurred.
12. The method of claim 9 , wherein the R-type voltage-dependent calcium channel inhibitor is administered during surgery to treat subarachnoid hemorrhage.
13. The method of claim 9 , wherein the R-type voltage-dependent calcium channel inhibitor is administered during surgery.
14. The method of claim 9 , wherein the subject does not have symptoms of cerebral vasospasm.
15. The method of claim 9 , wherein the subject has symptoms of cerebral vasospasm.